AsclepiX Therapeutics, Inc.
Bethesda, US · Founded 2023 · Delaware corporation · 2 known investors
Find your way into AsclepiX Therapeutics, Inc.
631 people in our graph share verified history with the AsclepiX Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.
Javier Solterounlockedknows Jordan J. Green · together at Carnegie Mellon University (overlapped)
×6knows the team · via Massachusetts Institute of Technology
knows the team · via Johns Hopkins University
×2knows the team · via Merck
knows the team · via Carnegie Mellon University
knows the team · via University System of Maryland Momentum Fund
Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
Founders & leadership
AsclepiX Therapeutics, Inc. was founded in 2023 by Aleksander S. Popel, PhD and Jordan J. Green.
AS
Aleksander S. Popel, PhDCo-founder
JJ
Jordan J. GreeninCo-Founder and Member of BODJordan J. Green is an Executive Officer and Director at AsclepiX Therapeutics, a biopharmaceutical company developing peptide therapies for eye diseases. He has expertise in molecular and cellular engineering, nanotechnology, biomedical engineering, biomaterials, drug delivery, and gene therapy.
WP
Wendy PerrowinChief Executive Officer and Board Member2016–2020Wendy Perrow is CEO of AsclepiX Therapeutics, a biopharmaceutical company developing peptide therapies for eye diseases. She has held executive leadership roles in pharmaceutical and biotech companies, with prior experience in drug launches and capital raising.
Investors · 2
Reported raises · per SEC filings
Form D private placements$28M disclosed across 4 rounds · 2017–2023
▶$10MraisedApr 2024 · 9 investors · BiotechnologyRule 506(b)
▶$10MraisedApr 2024 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert DempseyExecutive Officer
- Steven AltschulerDirector
- Ben AskewDirector
- Josh BarerDirector
- Chris GarabedianDirector
- Aleksander PopelExecutive Officer
- Sapna SrivastavaDirector
- Amir ShojaeiExecutive Officer
- Niranjan PandeyExecutive Officer
- Jill TierneyExecutive Officer
- Jordan GreenDirector
- Offering amount
- $12.5M
- Amount sold
- $10M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$10MraisedJun 2020 · 34 investors · BiotechnologyRule 506(b)
▶$10MraisedJun 2020 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sapna SrivastavaDirector
- Aleksander S. Popel, PhDDirector
- Jordan J. GreenDirector
- Kevin Slawin, MDExecutive Officer, Director
- Steven Altschuler, MDDirector
- Joshua BarerDirector
- Offering amount
- $35M
- Amount sold
- $10M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.7MraisedJun 2019 · 26 investors · BiotechnologyRule 506(b)
▶$7.7MraisedJun 2019 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven Altschuler, MDDirector
- Sapna SrivastavaDirector
- Joshua BarerDirector
- Kevin Slawin, MDDirector
- Aleksander S. Popel, PhDDirector
- Wendy PerrowExecutive Officer, Director
- Jordan J. GreenDirector
- Offering amount
- $10M
- Amount sold
- $7.7M
- Sales commissions
- $40K
- Proceeds to insiders
- $575K
- Placement agents
- Solebury Capital LLC
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$175KraisedFeb 2017 · 5 investors · BiotechnologyRule 506(b)
▶$175KraisedFeb 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aleksander S. Popel, PhDExecutive Officer, Director
- Jordan J. GreenExecutive Officer, Director
- Wendy PerrowExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $175K
- First sale
- Feb 2017
- Incorporated
- Limited Liability Company, Maryland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $278.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $260.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $258K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does AsclepiX Therapeutics, Inc. do?
- Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
- Who founded AsclepiX Therapeutics, Inc.?
- AsclepiX Therapeutics, Inc. was founded by Aleksander S. Popel, PhD, Jordan J. Green in 2023.
- Who are AsclepiX Therapeutics, Inc.'s investors?
- AsclepiX Therapeutics, Inc.'s investors include Rapha Capital Management, LLC, Perceptive Xontogeny Venture.
- How much funding has AsclepiX Therapeutics, Inc. raised?
- AsclepiX Therapeutics, Inc. has disclosed $28M raised across 4 rounds.
- Where is AsclepiX Therapeutics, Inc. headquartered?
- AsclepiX Therapeutics, Inc. is headquartered in Bethesda, US.